US › Healthcare

Atrium Therapeutics, Inc. Common Stock (RNA)

US · Healthcare · Biotechnology

$11.54+1.85%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$19.6M

Revenue YoY

+1148.3%

Net profit

$-16.6M

Profit YoY

+85.6%

EPS

$-0.97

EPS estimate

$-1.05

Net margin

-84.7%

EPS came in at -0.97 against a street estimate of -1.05 — a beat of 7.6%.

Key statistics

Market cap

$194.1M

Forward P/E

0.0

P/B

0.83

Book value

$13.69

EPS (TTM)

$-5.02

52-week high

$16.77

52-week low

$11.13

50-day MA

$12.48

200-day MA

$13.11

Beta

0.93

Analyst view

Analysts rate Atrium Therapeutics, Inc. Common Stock a strong buy (15 buy, 0 hold, 0 sell out of 15) with an average price target of $25.00.

Shareholding

Insiders

4.27%

Institutions

89.15%

Largest institutional holders

Fund	Stake
CIBC Bancorp USA Inc.	0.00%
Arizona State Retirement System	0.00%
Capital Analysts Inc.	0.00%
Acadian Asset Management LLC	0.00%
Carmignac Gestion	0.00%
Allianz Asset Management AG	0.00%
Cinctive Capital Management LP	0.00%
ARP AMERICAS LLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Atrium Therapeutics, Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.